AxoGen, Inc. to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 17 2016 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical
solutions for peripheral nerve injuries, today announced that Karen
Zaderej, President and Chief Executive Officer, will present at the
28th Annual Piper Jaffray Healthcare Conference in New York City at
the Lotte New York Palace. The presentation is scheduled for
Tuesday, November 29, 2016 at 9:50 am ET.
The presentation will be webcast live and can be
accessed through the Investors page at www.axogeninc.com. For those
not available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxoGen AxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen’s portfolio of products includes Avance® Nerve
Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix ("ECM") coaptation aid for
tensionless repair of severed nerves, and AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
injured peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments. Along with these core
surgical products, AxoGen also offers AxoTouch™ Two-Point
Discriminator and AcroVal™ Neurosensory & Motor Testing System.
These evaluation and measurement tools assist healthcare
professionals in detecting changes in sensation, assessing return
of sensory, grip and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom and several European and
international countries.
Cautionary Statements Concerning Forward-Looking
StatementsThis Press Release contains "forward-looking" statements
as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made, and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024